

Società Italiana di Allergologia, Asma ed Immunologia Clinica

FIRENZE 6/9 APRILE 2017 | WWW.SIAAIC2017.ORG

Nuove APPs in allergologia respiratoria

Marco Caminati

Unità Operativa di Allergologia Centro di riferimento regionale per la prevenzione, la diagnosi e la cura delle malattie allergiche Ospedale Universitario di Verona Responsabile G. Senna

Direttivo Junior Members SIAAIC

Co-Chair WAO JMs Steering Committee










DISCLOSURE OF INTEREST

I'intero supporto aziendale della presente sessione sponsorizzata ha integrato il budget dei JMs della SIAAIC per la patecipazione al congresso 2017

SIZING THE ISSUE


THE APP "TSUNAMI"



SIZING THE ISSUE


THE APP "TSUNAMI"

Prevalence (millions)



APPs AND HEALTH

WHY SHOULD THE APPs BE DOCTORS' BUSINESS?



APPs AND HEALTH

Publication	Disease	Treatment adherence rate (%)	Reasons for nonadherence	Strategies for improving adherence
Shingler et al., 2014 [10]	Cancer	20-88	Adverse events, patient beliefs, inadequate knowledge, disease progression, long treatment duration, and regimen complexity	Understanding of patient preference and home administration
Chowdhury et al., 2013 [11]; Kronish and Ye, 2013 [12]	Cardiovascular diseases	4.9-93.3	Adverse events, costs, uncertainty about effectiveness, concerns about medications, psychological disorders, polypharmacy, and inaccurate knowledge	Enhanced counseling and education, simplification of regimen and reminders (phone/e-mail/text messages), and collaboration with other healthcare professionals
de Achaval and Suarez-Almazor, 2010 [13]	Rheumatoid arthritis	11-92	Uncertainty about effectiveness, concerns about medications, psychological disorders, regimen complexity, poor knowledge, costs, patients' beliefs, polypharmacy, and low socioeconomic and educational status	Reminders (phone/ e-mail/text messages) and enhanced counseling and education
/ervioet et al., 2011 [14]	Diabetes	35-95	Polypharmacy, regimen complexity, poor knowledge, and low socioeconomic and educational status	Enhanced counseling and education, simplification of regimen and reminders (phone/e-mail/SMS), and collaboration with other healthcare professionals
Sumino and Cabana, 2013 [15]	Asthma	30-70	Uncertainty about effectiveness, concerns about medications, psychological disorders, polypharmacy, and inaccurate knowledge	Enhanced counseling and education, simplification of regimen, reminders (phone/e-mail/text messages), smartphone apps, and collaboration with other healthcare professionals
Restrepo et al., 2008 [16]	COPD	40-90	Uncertainty about effectiveness, concerns about medications, psychological disorders, polypharmacy, inadequate	Enhanced counselling, monitoring and feedback about inhaler use through electronic medication delivery

WHY SHOULD THE APPs BE DOCTORS' BUSINESS?


provide the patient with immediate feedback about their disease status

remind them about the appropriate treatment schedule

Senna, Caminati, Lockey Curr Treat Opt Allergy 2014

APPs AND HEALTH

WHY SHOULD THE APPs BE DOCTORS' BUSINESS?



IL PAZIENTE E L'INFORMAZIONE POLLINICA

QUANTO I PAZIENTI CONSULTANO IL WEB?





Fig 1. Tweet trend for ARC case definition, tweet trend for antihistamine drugs and US total pollen count. In the upper plot: the light blue line represents the weekly averages of tweets satisfying the ARC case definition; the dark blue line represents the weekly averages of tweets including the name of an antihistamine drug. Tweet trends are obtained from tweets which were geolocalized in the US and are plotted on different scales to emphasize the similarities of the trends. In the lower plot: the red solid line represents the sum of the total pollen counts obtained from all US stations; the shaded red areas represent the single city total pollen counts. The single city total pollen counts are represented on the same scales. The sum of the total pollen counts is plotted on a specific scale to allow trend comparison with the single city pollen counts. All trends represent weekly averages for the 35-week (242 day) period starting in week 5 (January 2013) through week 40 (September 2013).

Gesualdo et al, PlosONE 2015

IL PAZIENTE E L'INFORMAZIONE POLLINICA

QUANTO I PAZIENTI CONSULTANO IL WEB?




Mosges et al, Allergy 2011

Adolescent Asthma Assessment

PRELIMINARY RESULTS on 203 questionnaires

13. Pensi che gli strumenti sotto elencati possano aiutarti a ricordarti di assumere i farmaci regolarmente?

Social networks (Facebook, Tweeter)




Caminati, Lombardi et al, in preparation

Adolescent Asthma Assessment

PRELIMINARY RESULTS on 203 questionnaires

13. Pensi che gli strumenti sotto elencati possano aiutarti a ricordarti di assumere i farmaci regolarmente?

Smart phones con un applicazione di memo



Caminati, Lombardi et al, in preparation

questionario su uso/utilità delle APPs nelle allergopatie respiratorie

Studio multicentrico nazionale (23 centri partecipanti)

Sinora raccolti 438 questionari

12 items

Età media : 34 anni

6. effettui il download di APPs?

Si, ma solo qualche volta	82 %
🔵 no, mai	8 %

7. hai scaricato ancora APPs riguardanti il campo della salute/medicina?

🔿 no, mai	89 %
Si, ma solo qualche volta	10 %
Si, spesso	1%

APPs AND ALLERGIC RESPIRATORY DISEASES

WHAT DO WE KNOW?

Smartphone and tablet self management apps for asthma (Review)

Marcano Belisario JS, Huckvale K, Greenfield G, Car J, Gunn LH

☞ 2 RCTs

☞ 408 participants

The current evidence base is not sufficient to advise clinical practitioners, policy-makers and the general public with regards to the use of smartphone and tablet computer apps for the delivery of asthma self management programmes. In order to understand the efficacy of apps as standalone interventions, future research should attempt to minimise the differential clinical management of patients between control and intervention groups. Those studies evaluating apps as part of complex, multicomponent interventions, should attempt to tease out the relative contribution of each intervention component. Consideration of the theoretical constructs used to inform the development of the intervention would help to achieve this goal. Finally, researchers should also take into account: the role of ancillary components in moderating the observed effects, the seasonal nature of asthma and long-term adherence to self management practices.



APPs AND ALLERGIC RESPIRATORY DISEASES

WHAT ABOUT RHINITIS?



nasce per pazienti con asma e rinite

non validata né tradotta in italiano

scarsa "immediatezza" di compilazione

- > Know and monitor the degree of control of asthma and allergic rhinitis with CARAT
- Add your asthma/rhinitis medication and record medication use
- Set alarms to remind you when to take medications and other tasks such as medical appointments
- > Keep a record of your symptoms, attacks, pulmunary function and healthcare use
- customizable access to information about asthma/rhinitis

Burnay et al, Telemedicine e health 2013

A NEW TOOLS FOR PATIENTS AND DOCTORS





Figure 4 The MASK ICT strategy and usage.

Bousquet et al Allergy 2015

MACVIA*LR From clinical trials to patients in real life









Definition and Objectives

- •MASK (MACVIA-ARIA Sentinel Network) is the e-health tool that has been introduced into ARIA
- •The beginning of the pollen season will be monitored using patients as sentinels (novel approach)







Definition and Objectives

- •MASK (MACVIA-ARIA Sentinel Network) is the e-health tool that has been introduced into ARIA
- •The beginning of the pollen season will be monitored using patients as sentinels (novel approach)
- •MASK will function in conjunction with a clinical decision support system (CDSS) that will use the recommendations of ARIA 2015 to follow patients during allergen exposure and to adapt treatment according to regular rhinitis control

IN DAILY CLINICAL PRACTICE


 On first use, users see a welcome screen, accept terms and conditions of use and are given the opportunity to register and create an account.




IN DAILY CLINICAL PRACTICE


- Me
- Symptoms
- Medication

All information will be collected in an MACVIA ARIA database and can be used to stratify results



IN DAILY CLINICAL PRACTICE





The meds presented daily are
Linked to those included in the
User profile. User switches meds
On as appropriate

Drugs are listed by generic nameWith associated brand names


Additionale meds can be added

Multiple therapy usage will be apparent

IN DAILY CLINICAL PRACTICE

• An optional reminder to track symptoms and take medication is also included.


Aim: Improve treatment compliance



IN DAILY CLINICAL PRACTICE

- Impact of AR symptoms on patients' lives
 - According to ARIA severity classification
- A simple way to gauge severity

Moderate/severe patients can be easily identified and treated appropriately




AR: allergic rhinitis

IN DAILY CLINICAL PRACTICE

- What symptoms in particular?
 - 4 nasal symptoms
 - 3 ocular symptoms
- Users can select and deselect and edit if their symptom pattern changes

Permits a rapid assessment of patients' symptom pattern




My Allergy Diary: Symptom Control



• Based on a VAS

MACVIA*LR


- Users measure allergic symptoms (finger+phone)
- Reply to questions by placing finger on VAS
- Users touch the line to indicate response and a 'marker' appears in that location
- The marker can be moved with a finger to mark the line where intended.
- Once the mark is placed the user then touches 'next' to move on to the next VAS
- Each VAS is completed once daily




IN DAILY CLINICAL PRACTICE

- In case of continued high scores the feedback message will display an appropriate message in red type and a warning icon will mark the graph
 - Prompts users to discuss their diary data with their health care provider

Aim: Get to 'green' and stay there



IN DAILY CLINICAL PRACTICE



• The overall AR symptom VAS responses are displayed in portrait view; by rotating to landscape view all VAS responses can be seen

POTENTIAL ADVANTAGES IN DAILY CLINICAL PRACTICE – HCP PERSPECTIVE

- ✓ Immediata visualizzazione del diario dei sintomi e dei farmaco
- ✓ Immediata visualizzazione dell'effettivo regime di trattamento
- ✓ Vantaggio nell'impostazione di nuove terapie
- ✓ Valutazione delle necessità terapeutiche nel corso della stagione
- ✓ Individuazione dei pazienti non controllati dopo la stagione per impostare un nuovo piano terapeutico

POTENTIAL ADVANTAGES IN DAILY CLINICAL PRACTICE – PATIENT PERSPECTIVE

- ✓ Individuazione precoce dei sintomi e della stagione pollinica
- ✓ Maggior consapevolezza dei propri sintomi e della malattia
- ✓ Durata ottimale del trattamento
- Miglior controllo della malattia sulla base di protocolli terapeutici raccomandati da esperti per controllare i sintomi e prevenire forme severe
- ✓ Facilità e immediatezza d'uso
- ✓ self-regulation with support (aderenza, cinsapevolezza)

ALLERGY APPs

POTENTIAL DRAWBACKS

✓ "Tacita complicità" nell'auto-medicazione / autogestione



A TAILORED APPROACH

☞ Informazione / Educazione

🖙 Awareness dei rischi potenziali della propria patologia

☞ Coinvolgimento di altri HCPs

ADVANTAGES IN DAILY CLINICAL PRACTICE – HCP PERSPECTIVE




Figure 8 ICP for MASK-rhinitis.

ALLERGY APPs

WHAT DO PATIENTS WANT?

Immediate feedback

Immediate relief



(2015) 13:17	
Rossi et al. Clinical and Molecular Allergy	DOI 10.1186/s12948-015-0023-y

CLINICAL AND MOLECULAR ALLERGY

REVIEW

Open Access

Escaping the trap of allergic rhinitis



Oliviero Rossi^{1*}, Ilaria Massaro^{2†}, Marco Caminati³⁺, Cristina Quecchia⁴⁺, Filippo Fassio^{5†}, Enrico Heffler^{6†} and Giorgio Walter Canonica^{7†}

Abstract

However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become ronically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. intolerable' and often when their usual therapy proves ineffective.

Clearly, it's time for new and more effective allergic rhinitis treatments.

perennial allergic rhinitis if monotherapy with either intranasal antihistamine or intranasal corticosteroids is not MP29-02 (Dymista®; Meda, Solna, Sweden) is a new class of medication for moderate to severe seasonal and considered sufficient.

droplet size, larger volume (137 µl) and wider spray angle ensure optimal coverage of, and retention on the nasal mucosa MP29-02 is a novel formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP). It benefits not only from the incorporation of two active agents, but also from a novel formulation; its lower viscosity, smaller and contribute to its clinical efficacy.

those patients for whom nasal congestion is predominant, with MP29-02 providing three times the nasal congestion relief FP was approximately the same as that shown for FP over placebo. The advantage of MP29-02 was particularly evident in who in turn exhibited significantly greater symptom relief than placebo-patients. Indeed, the advantage of MP29-02 over the perception of well-controlled disease after only 3 days. MP29-02's superiority over FP was also apparent long-term in and every response up to a week faster than those treated with FP or AZE alone and in real life 1 in 2 patients reported n clinical trials, patients treated with MP29-02 experienced twice the symptom relief as those treated with FP and AZE, of FP (p = 0.0018) and five times the relief of AZE (p = 0.0001). Moreover, patients treated with MP29-02 achieved each patients with perennial allergic rhinitis or non-allergic rhinitis, with statistical significance noted from the first day of treatment, with treatment difference maintained for a full year.

Taken together, these data suggest that MP29-02 may improve the lives of many of our patients, enabling them to finally escape the allergic rhinitis trap.

Keywords: Allergic rhinitis, Intranasal corticosteroids, Intranasal antihistamines, Therapy

GRAZIE ma.caminati@gmail.com



